Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jett, J. R.
Right arrow Articles by Sause, W. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jett, J. R.
Right arrow Articles by Sause, W. T.
(Chest. 2003;123:221S-225S.)
© 2003 American College of Chest Physicians

Guidelines on Treatment of Stage IIIB Non-small Cell Lung Cancer*

James R. Jett, MD, FCCP; Walter J. Scott, MD, FCCP; M. Patricia Rivera, MD, FCCP and William T. Sause, MD, FACR

* From the Mayo Clinic (Dr. Jett), Rochester, MN; Section of Thoracic Surgical Oncology, Fox Chase Cancer Center (Dr. Scott), Philadelphia, PA; University of North Carolina (Dr. Rivera), Chapel Hill, NC; LDS Hospital, University of Utah (Dr. Sause), Salt Lake City, UT.

Correspondence to: James R. Jett, MD, FCCP, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905;

Stage IIIB includes patients with T4, any N, M0, and any T, N3, M0. Surgery may be indicated only for carefully selected T4N0M0 patients with or without neoadjuvant chemotherapy or chemoradiotherapy. Patients with N3 lymph node involvement are not considered as surgical candidates. For patients with unresectable disease, good performance score, and minimal weight loss, treatment with combined chemotherapy and radiotherapy has resulted in better survival than treatment with radiotherapy alone. Multiple daily fractions of radiotherapy have not resulted in improved survival compared with standard fractionation once daily. Concurrent chemoradiotherapy appears to be associated with improved survival compared with sequential chemotherapy and radiotherapy. Treatment of stage IIIB due to malignant pleural effusion is addressed in the section that deals with stage IV disease.

Key Words: NSCLC stage IIIB • stage IIIB • unresectable lung cancer • unresectable NSCLC






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Chest Physicians.